Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease

NCT04815187 is registered in ClinicalTrials.gov with House Ear Institute as lead sponsor.

NCT NCT04815187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04815187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
Lead sponsor
House Ear Institute
Phase
Phase 4
Overall status
Active, not recruiting
Start date
June 7, 2021
Completion date
December 31, 2025
Enrollment
39 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

allergic rhinitis, meniere disease, vertigo